Home > Keywords > Thématique > Agenda

Agenda

Articles

  • FEDER
    16 March 2022, by Jonathan NOWAK

    Vect Horus a reçu l’accord de la Région Sud Provence-Alpes-Côte d’Azur, responsable de la mise en œuvre du dispositif REACT-EU dans le cadre du Programme Opérationnel FEDER-FSE, pour une subvention de 1 146 069 €.
    Vect-Horus développe sa plateforme technologique VECTrans® unique en Europe dont l’objectif est de développer des molécules « vecteurs » qui permettent le ciblage et la délivrance d’agents d’imagerie ou thérapeutiques dans des organes spécifiques. Cette stratégie est centrale, en (…)

  • Meet Vect-Horus at BIO Japan, October 8-10, 202
    19 September, by Emmanuelle BETTENDORF

    We are excited to be attending BioJapan, taking place October 8-10.
    Our Senior Business Developer Faustine Ramel will be in Yokohama for the event – please let us know if you would like to schedule a meeting.
    https://jcd-expo.jp/en/

  • Vect-Horus will be attending BIO Europe from the 24th - 26th October in Germany
    20 October 2022, by Elodie DORMES

    This is the first in person BIOEurope since 2019 and we are excited to meet everyone face-to-face again.
    Feel free to connect with Emmanuelle BETTENDORF on the platform for a meeting/coffee to discuss our DrugDelivery platform, amongt others in Neurodegenerative, Muscular, Cardiovascular and Eye diseases.

  • Meet Vect-Horus at BIO Spring Basel, Switzerland, March 20–22, 2023
    17 February 2023, by Elodie DORMES

    Emmanuelle BETTENDORF will participate in BioEurope Spring from March 20 to 22, 2023 and will be available to meet with you on partnership opportunities.

  • Vect-Horus Nominated for the 2024 Biotech Trophy Award, Organized by France Biotech
    21 March 2024, by Emmanuelle BETTENDORF

    Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced it has been nominated for the 2024 Biotech Trophy award, organized by the France Biotech industry association.
    The award recognizes a biotech company which has distinguished itself in the past two years by particularly remarkable advances in R&D, operational development, partnerships or (…)

  • Participation au BIOREZO™ Vectorisation : de l’imagerie à la thérapeutique
    28 January 2019, by Jonathan NOWAK

    Participation au BIOREZO™ VECTORISATION : DE L’IMAGERIE À LA THÉRAPEUTIQUE

  • Vect-Horus attends to the NLSDays
    29 April 2021, by Elodie DORMES

    Connect with Emmanuelle BETTENDORF Sr. Business Developer at this year’s digital NORDIC LIFE SCIENCES through the event’s One-on-One Partnering.

  • Meet Vect-Horus at OTS, Montreal, October 6-9, 2024
    2 October 2024, by Emmanuelle BETTENDORF

    Guillaume Jacquot and Emmanuelle Bettendorf will be representing Vect-Horus at the The Oligonucleotide Therapeutics Society (OTS) Annual Meeting, taking place in Montreal, Canada from October 6-9.
    This is the leading international meeting of renowned oligonucleotide scientists, bringing academia, research and business together, and we are excited to swap notes with other leading players in the field.
    👉 Click here for more on the meeting www.2024oligomeeting.com

  • Happy new year !
    24 December 2021, by Elodie DORMES

    The Vect-Horus teams join to wish you a Happy Holiday season and Best Wishes for 2022.

  • Nanomedicine for treating cancer and brain diseases symposium in MARSEILLE
    6 March 2019, by Jonathan NOWAK

    In the context of the Euronanomed projects for Action on Nanomedicine under Horizon 2020, a Symposium will be held at the Luminy campus in Marseille on March 8, 2019. Dr. Khrestchatisky will give a talk titled "Molecular vectors for drug delivery into the brain and tumors".
    For more information, please visit the symposium website or download the pdf version of the program.